Personalis/$PSNL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Ticker
$PSNL
Sector
Primary listing
Employees
229
Headquarters
Website
Personalis Metrics
BasicAdvanced
$519M
-
-$1.18
1.87
-
Price and volume
Market cap
$519M
Beta
1.87
52-week high
$7.79
52-week low
$2.83
Average daily volume
1M
Financial strength
Current ratio
6.095
Quick ratio
5.774
Long term debt to equity
17.93
Total debt to equity
22.671
Interest coverage (TTM)
-877.98%
Profitability
EBITDA (TTM)
-61.575
Gross margin (TTM)
31.45%
Net profit margin (TTM)
-113.70%
Operating margin (TTM)
-89.64%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-20.26%
Return on equity (TTM)
-60.26%
Valuation
Price to revenue (TTM)
5.643
Price to book
2.72
Price to tangible book (TTM)
2.72
Price to free cash flow (TTM)
-9.215
Free cash flow yield (TTM)
-10.85%
Free cash flow per share (TTM)
-0.635
Growth
Revenue change (TTM)
0.36%
Earnings per share change (TTM)
-27.15%
3-year revenue growth (CAGR)
1.68%
3-year earnings per share growth (CAGR)
-17.31%
What the Analysts think about Personalis
Analyst ratings (Buy, Hold, Sell) for Personalis stock.
Bulls say / Bears say
Clinical test volume jumped 59% sequentially to 3,478 tests in Q2 2025—up from 2,184 in Q1—showing faster uptake of the NeXT Personal® platform by doctors (Business Wire)
Personalis expanded its exclusive commercialization agreement with Tempus AI to now cover colorectal cancer, significantly increasing its market potential and strengthening its commercial partnership in a key new area (Business Wire)
Pharma tests and services revenue rose 39% year-over-year to $13.6 million in Q1 2025, boosting total revenues to $20.6 million and reflecting strong demand for Personalis’ genomic sequencing and analytics offerings (Business Wire)
Q2 2025 revenue dropped 24% year-over-year to $17.2 million, coming in below the Q1 outlook of $19.5–20.5 million, highlighting the impact of timing fluctuations in biopharma projects (Business Wire)
Personalis lowered its full-year 2025 revenue forecast by 12.5% at the midpoint, reducing the range from $80–90 million down to $70–80 million, citing delays in key biopharma contract revenue (Investing.com)
Gross margin shrank by eight percentage points to 27.6% in Q2 2025 driven by lower volume and higher costs for clinical tests not reimbursed, putting profitability under pressure (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Personalis Financial Performance
Revenues and expenses
Personalis Earnings Performance
Company profitability
Personalis News
AllArticlesVideos
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire3 hours ago
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
Business Wire5 days ago
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Personalis stock?
Personalis (PSNL) has a market cap of $519M as of September 16, 2025.
What is the P/E ratio for Personalis stock?
The price to earnings (P/E) ratio for Personalis (PSNL) stock is 0 as of September 16, 2025.
Does Personalis stock pay dividends?
No, Personalis (PSNL) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Personalis dividend payment date?
Personalis (PSNL) stock does not pay dividends to its shareholders.
What is the beta indicator for Personalis?
Personalis (PSNL) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.